AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26157075 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 855 (pegylated full-length recombinant FVIII)
Number of subjects: 0
Study 26157075 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment (licensed rFVIII - Advate)
Number of subjects: 0
Study 26157075 — intervention group
Group type: EXPERIMENTAL
Intervention: BAX 855 (for treatment of bleeding episodes)
Number of subjects: 0
Study 26158159 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combination with oxaliplatin and oral leucovorin (SOL regimen)
Number of subjects: 21
Study 26158171 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa/ribavirin
Number of subjects: 1604
Study 26160357 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant 24-h infusion (16.5 μg/day)
Number of subjects: 0
Study 26160357 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant 7-day infusion (25.5 μg/day in Cohort 2)
Number of subjects: 0
Study 26160357 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day escalation regimen (ranging from 7 to 58.5 μg/day in Cohort 1)
Number of subjects: 0
Study 26160357 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day escalation regimen (25.5-58.5 μg/day in Cohort 3)
Number of subjects: 0
Study 26160457 — intervention group
Group type: EXPERIMENTAL
Intervention: FTCQ-12 (French Tobacco Craving Questionnaire 12-item)
Number of subjects: 0
Study 26160457 — intervention group
Group type: EXPERIMENTAL
Intervention: MNWS craving (Minnesota Nicotine Withdrawal Scale single craving item)
Number of subjects: 0
Study 26160457 — intervention group
Group type: EXPERIMENTAL
Intervention: FTCQ-12 RS (risk score from FTCQ-12)
Number of subjects: 0
Study 26160457 — intervention group
Group type: EXPERIMENTAL
Intervention: FTCQ-12 RS and MNWS craving combined
Number of subjects: 0
Study 26160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting Expectancy and Purposefulness
Number of subjects: 0
Study 26160744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment (oseltamivir or zanamivir) in 474 patients.
Number of subjects: 914
Study 26160744 — intervention group
Group type: COMPARATOR
Intervention: B/Victoria lineage
Number of subjects: 914
Study 26160744 — intervention group
Group type: COMPARATOR
Intervention: B/Yamagata lineage
Number of subjects: 914
Study 26160880 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (10 mg) combined with idarubicin (8 mg/m(2) iv days 1-3) and cytarabine (100 mg/m(2) iv days 1-7) during induction, followed by panobinostat maintenance (40 mg po 3 days/week) every other week until progression.
Number of subjects: 38
Study 26160880 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat monotherapy during maintenance phase for patients with persistent minimal residual disease.
Number of subjects: 38
Study 26160880 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat maintenance phase.
Number of subjects: 38
Study 26161281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy with double tract reconstruction (LPG with DTR)
Number of subjects: 0
Study 26161281 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 0
Study 26161450 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα soluble receptors 1 (TNFα-sR1)
Number of subjects: 400
Study 26161450 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα soluble receptors 2 (TNFα-sR2)
Number of subjects: 400
Study 26161450 — intervention group
Group type: COMPARATOR
Intervention: PUFA intake
Number of subjects: 400
Study 26161618 — intervention group
Group type: EXPERIMENTAL
Intervention: AXL1717, 390 mg BID for four weeks (RP2D)
Number of subjects: 55
Study 26162031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) treatment
Number of subjects: 108
Study 26162676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenges (FCs)
Number of subjects: 2213
Study 26162857 — intervention group
Group type: EXPERIMENTAL
Intervention: J-CTO score
Number of subjects: 650
Study 26162857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade wiring techniques
Number of subjects: 650
Study 26162857 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde approach
Number of subjects: 650
Study 26162857 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for technical success
Number of subjects: 650
Study 26163041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy (initiation within 24 hours of hospital admission)
Number of subjects: 11944
Study 26163041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy
Number of subjects: 11944
Study 26163041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy in urban hospitals
Number of subjects: 11944
Study 26163041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel therapy in rural hospitals
Number of subjects: 11944
Study 26163849 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fujita Technique Uvulopalatoplasty (UPPP)
Number of subjects: 0
Study 26163849 — intervention group
Group type: COMPARATOR
Intervention: CPAP treatment
Number of subjects: 0
Study 26163959 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesiolysis during repeat median laparotomy
Number of subjects: 259
Study 26163959 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous laparotomies
Number of subjects: 259
Study 26163959 — intervention group
Group type: EXPERIMENTAL
Intervention: History of peritonitis, anatomical location of previous surgery, time interval between consecutive median laparotomies
Number of subjects: 259
Study 26163959 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or history of an intraperitoneal synthetic mesh
Number of subjects: 259
Study 26164539 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-7 generated elastin fragments (ELM7) in patients with IPF
Number of subjects: 163
Study 26164539 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-7 generated elastin fragments (ELM7) in patients with lung cancer
Number of subjects: 163
Study 26167342 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group DL)
Number of subjects: 150
Study 26167342 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2 laryngoscope (Group TW)
Number of subjects: 150
Study 26167342 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (Group ATQ)
Number of subjects: 150
Study 26167947 — intervention group
Group type: EXPERIMENTAL
Intervention: AvidinOX-pretargeted (90)Y-biotinDOTA
Number of subjects: 1
Study 26167947 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 26168005 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-attributable GP episodes for respiratory illness in children aged <5 years
Number of subjects: 857996
Study 26168005 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-attributable GP episodes for respiratory illness in seniors aged ≥75 years
Number of subjects: 857996
Study 26168005 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescriptions resulting from influenza-attributable GP episodes
Number of subjects: 857996
Study 26169157 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum adiponectin concentrations measured by DuoSet® ELISA
Number of subjects: 1193
Study 26169157 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference intervals calculated using age as a continuous variable
Number of subjects: 1193
Study 26169192 — intervention group
Group type: EXPERIMENTAL
Intervention: CONTOUR(®)PLUS
Number of subjects: 106
Study 26169270 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection
Number of subjects: 0
Study 26169613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (150 to 300 mg/d)
Number of subjects: 43
Study 26169615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 87
Study 26169615 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-1 [(18)F]FDG-PET/CT response
Number of subjects: 87
Study 26169889 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sampling combined assessment of medium-sensitivity cardiac troponin I and ultra-sensitive copeptin
Number of subjects: 196
Study 26169889 — intervention group
Group type: COMPARATOR
Intervention: Serial 0- and 3-hour medium-sensitivity cardiac troponin I sampling
Number of subjects: 196
Study 26170105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 162
Study 26170136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir (25 mg), Paritaprevir (150 mg), and Ritonavir (100 mg) once daily for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)
Number of subjects: 181
Study 26170136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir, and Ritonavir regimen
Number of subjects: 181
Study 26170350 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 50
Study 26170350 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 50
Study 26170350 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 50
Study 26170650 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure patients
Number of subjects: 106
Study 26170650 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure with reduced ejection fraction
Number of subjects: 106
Study 26170650 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD presence in heart failure with preserved ejection fraction
Number of subjects: 106
Study 26170650 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected cases of COPD in heart failure patients
Number of subjects: 106
Study 26170884 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 15
Study 26171276 — intervention group
Group type: EXPERIMENTAL
Intervention: V1512 (melevodopa 100 mg/carbidopa 25 mg)
Number of subjects: 25
Study 26171276 — intervention group
Group type: COMPARATOR
Intervention: L-dopa 100 mg/carbidopa 25 mg
Number of subjects: 25
Study 26171276 — intervention group
Group type: EXPERIMENTAL
Intervention: V1512 or L-dopa/carbidopa in combination with entacapone 200 mg
Number of subjects: 25
Study 26171659 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle(®) Libre™ Flash glucose monitoring system
Number of subjects: 72
Study 26171795 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIN3 knockdown in myotubes from leans
Number of subjects: 29
Study 26171795 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipolytic stimulation (palmitate, forskolin, inomycin [PFI] cocktail)
Number of subjects: 29
Study 26171795 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with brefeldin A (BFA)
Number of subjects: 29
Study 26171795 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIN3 protein content
Number of subjects: 29
Study 26172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed story recall
Number of subjects: 0
Study 26172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living
Number of subjects: 0
Study 26172205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal mitomycin C (PL-MLP) at doses of 0.5-3.5 mg/kg every 4 weeks for up to 12 cycles
Number of subjects: 27
Study 26173796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment
Number of subjects: 63
Study 26174168 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of baseline BMI Z-scores (ages 8-10 years)
Number of subjects: 182
Study 26174168 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific BMI Z-scores at all youth clinic visits
Number of subjects: 182
Study 26174313 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients (IN)
Number of subjects: 178
Study 26174313 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients (OUT)
Number of subjects: 178
Study 26174798 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular global function index (LVGFI)
Number of subjects: 795
Study 26174798 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 795
Study 26175478 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 3010
Study 26175478 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3010
Study 26175501 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-339-5p (upregulated)
Number of subjects: 9
Study 26175501 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-483-3p (upregulated)
Number of subjects: 9
Study 26175501 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-139-5p (downregulated)
Number of subjects: 9
Study 26175532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology providers' documentation of falls
Number of subjects: 125
Study 26175532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait assessment by oncology providers
Number of subjects: 125
Study 26175532 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to geriatrics or physical/occupational therapy
Number of subjects: 125
Study 26175532 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of 25-hydroxy vitamin D level
Number of subjects: 125
Study 26176325 — intervention group
Group type: EXPERIMENTAL
Intervention: K+D group (90 μg of vitamin K2 and 10 μg of cholecalciferol)
Number of subjects: 42
Study 26176325 — intervention group
Group type: COMPARATOR
Intervention: D group (10 μg of cholecalciferol)
Number of subjects: 42
Study 26176325 — intervention group
Group type: EXPERIMENTAL
Intervention: K+D group
Number of subjects: 42
Study 26176325 — intervention group
Group type: COMPARATOR
Intervention: D group
Number of subjects: 42
Study 26176329 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SAP antibody infusion after CPHPC treatment
Number of subjects: 15
Study 26176329 — intervention group
Group type: EXPERIMENTAL
Intervention: CPHPC treatment
Number of subjects: 15
Study 26176329 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SAP antibody infusion
Number of subjects: 15
Study 26176493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin D levels (<30 ng/ml)
Number of subjects: 173
Study 26176493 — intervention group
Group type: COMPARATOR
Intervention: Normal vitamin D levels (≥30 ng/ml)
Number of subjects: 173
Study 26176696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in therapy with intravenous silibinin 20 mg/kg/day for 14 days followed by triple-therapy (peginterferon-ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks.
Number of subjects: 16
Study 26176696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in therapy with intravenous silibinin
Number of subjects: 16
Study 26177212 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Campylobacter concisus, Campylobacter rectus, Selenomonas infelix, Porphyromonas endodontalis, Porphyromonas gingivalis, Tannerella forsythia
Number of subjects: 0
Study 26177212 — intervention group
Group type: EXPERIMENTAL
Intervention: Campylobacter concisus, C. rectus, S. infelix
Number of subjects: 0
Study 26177212 — intervention group
Group type: EXPERIMENTAL
Intervention: Eubacterium saphenum, Eubacterium nodatum, Filifactor alocis
Number of subjects: 0
Study 26177212 — intervention group
Group type: EXPERIMENTAL
Intervention: Porphyromonas endodontalis, Parvimonas micra
Number of subjects: 0
Study 26177495 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 330
Study 26177495 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS (control group)
Number of subjects: 330
Study 26177651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime pesticide use (intensity-weighted) of specific pesticides
Number of subjects: 55880
Study 26177651 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one medical visit due to pesticide use
Number of subjects: 55880
Study 26177651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisation due to pesticide use
Number of subjects: 55880
Study 26177970 — intervention group
Group type: EXPERIMENTAL
Intervention: AdhAQP1
Number of subjects: 11
Study 26178412 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2862277 (modified dAb)
Number of subjects: 0
Study 26178412 — intervention group
Group type: COMPARATOR
Intervention: GSK1995057 (parent dAb)
Number of subjects: 0
Study 26178526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/d for 3 months
Number of subjects: 28
Study 26178723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 25-hydroxyvitamin D concentrations (25(OH)D)
Number of subjects: 1683
Study 26178723 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations <50 nmol/L
Number of subjects: 1683
Study 26178723 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations
Number of subjects: 1683
Study 26179143 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurement (SpHb; Radical-7 Pulse Co-Oximeter)
Number of subjects: 60
Study 26179143 — intervention group
Group type: COMPARATOR
Intervention: Blood gas analyzer (BGAHb; ABL 800 Flex)
Number of subjects: 60
Study 26179143 — intervention group
Group type: COMPARATOR
Intervention: Laboratory hematology analyzer (labHb; Siemens Advia)
Number of subjects: 60
Study 26179147 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing personal smoking environments (PSEs)
Number of subjects: 40
Study 26179200 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab 900 mg, 1350 mg, or 2000 mg every 2 weeks (dose-escalation phase) and 1000 mg every 2 weeks (dose-expansion phase)
Number of subjects: 25
Study 26179200 — intervention group
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Number of subjects: 25
Study 26180085 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK1 inhibitor (GS-444217 delivered in chow) - early intervention (2-8 weeks after STZ)
Number of subjects: 0
Study 26180085 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK1 inhibitor (GS-444217 delivered in chow) - late intervention (weeks 8-15 after STZ)
Number of subjects: 0
Study 26180085 — intervention group
Group type: COMPARATOR
Intervention: Control (normal chow) - diabetic Nos3(-/-) mice
Number of subjects: 0
Study 26180085 — intervention group
Group type: COMPARATOR
Intervention: Control (normal chow) - nondiabetic Nos3(-/-) mice
Number of subjects: 0
Study 26181029 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy for 13 days
Number of subjects: 1
Study 26181029 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 1
Study 26181029 — intervention group
Group type: EXPERIMENTAL
Intervention: HNSCC cells with MAPK1 E322K
Number of subjects: 1
Study 26181034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Emitter Radium 223
Number of subjects: 0
Study 26181354 — intervention group
Group type: EXPERIMENTAL
Intervention: T790M-specific EGFR inhibitor
Number of subjects: 0
Study 26181354 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26181891 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone therapy
Number of subjects: 57
Study 26181941 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring Cerebral Autoregulation
Number of subjects: 0
Study 26182309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 308
Study 26182684 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe reactions to tomato
Number of subjects: 0
Study 26182684 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of IgE to rPru p3
Number of subjects: 0
Study 26182684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild tomato allergy symptoms
Number of subjects: 0
Study 26182860 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 212
Study 26183005 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental SG-AR level 1
Number of subjects: 359
Study 26183005 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental SG-AR levels 4-5
Number of subjects: 359
Study 26183044 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant drug therapy with oxaliplatin and capecitabine (and panitumumab for patients without KRAS, BRAF, and PIK3CA mutations)
Number of subjects: 67
Study 26183076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative related-donor allo-BMT with post-transplantation rituximab and high-dose post-transplantation cyclophosphamide (PTCy)
Number of subjects: 83
Study 26184520 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 503
Study 26184520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 26184612 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable TAVR system
Number of subjects: 996
Study 26185103 — intervention group
Group type: EXPERIMENTAL
Intervention: DS Titanium Ligation Clip
Number of subjects: 502
Study 26185328 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26185466 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release morphine sulfate with sequestered naltrexone hydrochloride (MSN)
Number of subjects: 684
Study 26185680 — intervention group
Group type: EXPERIMENTAL
Intervention: Session-introducing intervention with mindfulness elements
Number of subjects: 150
Study 26185680 — intervention group
Group type: COMPARATOR
Intervention: Session-introducing progressive muscle relaxation
Number of subjects: 150
Study 26185680 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 150
Study 26185773 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 0.5 mg/kg
Number of subjects: 31
Study 26185773 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 1.0 mg/kg
Number of subjects: 31
Study 26185773 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 2.0 mg/kg
Number of subjects: 31
Study 26185773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26185773 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 31
Study 26186012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg every two weeks or 7.5 mg/kg every three weeks) combined with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks)
Number of subjects: 69
Study 26186012 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with modified FOLFOX6
Number of subjects: 69